Peptide Therapeutics Contract API Manufacturing Market Size, Share, and Trends 2025 to 2034

The global peptide therapeutics contract API manufacturing market size is calculated at USD 3.84 billion in 2025 and is forecasted to reach around USD 8.36 billion by 2034, accelerating at a CAGR of 9.04% from 2025 to 2034. The North America market size surpassed USD 1.48 billion in 2024 and is expanding at a CAGR of 9.14% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : June 2025  |  Report Code : 6262  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Peptide Therapeutics Contract API Manufacturing Market 

5.1. COVID-19 Landscape: Peptide Therapeutics Contract API Manufacturing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Peptide Therapeutics Contract API Manufacturing Market, By Scale of operation

8.1. Peptide Therapeutics Contract API Manufacturing Market Revenue and Volume, by Scale of operation

8.1.1 Lith Pre-clinicalium

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Clinical    

8.1.2.1. Market Revenue and Volume Forecast

Chapter 9. Global Peptide Therapeutics Contract API Manufacturing Market, By The synthesis method

9.1. Peptide Therapeutics Contract API Manufacturing Market Revenue and Volume, by The synthesis method

9.1.1. Non-chemical synthesis

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Chemical synthesis

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Peptide Therapeutics Contract API Manufacturing Market, By Enterprise type

10.1. Peptide Therapeutics Contract API Manufacturing Market Revenue and Volume, by Enterprise type

10.1.1. Large enterprise

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Small and medium enterprises

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global Peptide Therapeutics Contract API Manufacturing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Scale of operation

11.1.2. Market Revenue and Volume Forecast, by The synthesis method

11.1.3. Market Revenue and Volume Forecast, by Enterprise type

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Scale of operation

11.1.4.2. Market Revenue and Volume Forecast, by The synthesis method

11.1.4.3. Market Revenue and Volume Forecast, by Enterprise type

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Scale of operation

11.1.5.2. Market Revenue and Volume Forecast, by The synthesis method

11.1.5.3. Market Revenue and Volume Forecast, by Enterprise type

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Scale of operation

11.2.2. Market Revenue and Volume Forecast, by The synthesis method

11.2.3. Market Revenue and Volume Forecast, by Enterprise type

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Scale of operation

11.2.4.2. Market Revenue and Volume Forecast, by The synthesis method

11.2.4.3. Market Revenue and Volume Forecast, by Enterprise type

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Scale of operation

11.2.5.2. Market Revenue and Volume Forecast, by The synthesis method

11.2.5.3. Market Revenue and Volume Forecast, by Enterprise type

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Scale of operation

11.2.6.2. Market Revenue and Volume Forecast, by The synthesis method

11.2.6.3. Market Revenue and Volume Forecast, by Enterprise type

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Scale of operation

11.2.7.2. Market Revenue and Volume Forecast, by The synthesis method

11.2.7.3. Market Revenue and Volume Forecast, by Enterprise type

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Scale of operation

11.3.2. Market Revenue and Volume Forecast, by The synthesis method

11.3.3. Market Revenue and Volume Forecast, by Enterprise type

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Scale of operation

11.3.4.2. Market Revenue and Volume Forecast, by The synthesis method

11.3.4.3. Market Revenue and Volume Forecast, by Enterprise type

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Scale of operation

11.3.5.2. Market Revenue and Volume Forecast, by The synthesis method

11.3.5.3. Market Revenue and Volume Forecast, by Enterprise type

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Scale of operation

11.3.6.2. Market Revenue and Volume Forecast, by The synthesis method

11.3.6.3. Market Revenue and Volume Forecast, by Enterprise type

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Scale of operation

11.3.7.2. Market Revenue and Volume Forecast, by The synthesis method

11.3.7.3. Market Revenue and Volume Forecast, by Enterprise type

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Scale of operation

11.4.2. Market Revenue and Volume Forecast, by The synthesis method

11.4.3. Market Revenue and Volume Forecast, by Enterprise type

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Scale of operation

11.4.4.2. Market Revenue and Volume Forecast, by The synthesis method

11.4.4.3. Market Revenue and Volume Forecast, by Enterprise type

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Scale of operation

11.4.5.2. Market Revenue and Volume Forecast, by The synthesis method

11.4.5.3. Market Revenue and Volume Forecast, by Enterprise type

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Scale of operation

11.4.6.2. Market Revenue and Volume Forecast, by The synthesis method

11.4.6.3. Market Revenue and Volume Forecast, by Enterprise type

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Scale of operation

11.4.7.2. Market Revenue and Volume Forecast, by The synthesis method

11.4.7.3. Market Revenue and Volume Forecast, by Enterprise type

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Scale of operation

11.5.2. Market Revenue and Volume Forecast, by The synthesis method

11.5.3. Market Revenue and Volume Forecast, by Enterprise type

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Scale of operation

11.5.4.2. Market Revenue and Volume Forecast, by The synthesis method

11.5.4.3. Market Revenue and Volume Forecast, by Enterprise type

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Scale of operation

11.5.5.2. Market Revenue and Volume Forecast, by The synthesis method

11.5.5.3. Market Revenue and Volume Forecast, by Enterprise type

Chapter 12. Company Profiles

12.1. Bachem Group (Switzerland)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. CordenPharma (Germany)

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Lonza (Switzerland)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. PolyPeptide Group (Sweden)                       

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. AmbioPharm Inc. (U.S.)

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. WuXi AppTec (China)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. CEM Corporation (U.S.)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Thermo Fisher Scientific Inc. (U.S.)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. JITSUBO CO, LTD. (Japan)

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. ChemPartner (China)

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global peptide therapeutics contract API manufacturing market is expected to increase from USD 3.52 billion in 2024 to USD 8.36 billion by 2034.

The peptide therapeutics contract API manufacturing marketis expected to grow at a compound annual growth rate (CAGR) of around 9.04% from 2025 to 2034.

The major players in the peptide therapeutics contract API manufacturing market include Bachem Group (Switzerland), CordenPharma (Germany), Lonza (Switzerland), PolyPeptide Group (Sweden), AmbioPharm Inc. (U.S.) , WuXi AppTec (China), CEM Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), JITSUBO CO, LTD. (Japan), ChemPartner (China), ApexBio Technology (U.S.), Biotage (Sweden), AnaSpec (U.S.), Syngene International Limited (India), BCNPeptides (Spain), CPC Scientific Inc. (U.S.), Creative Peptides (U.S.), CSBio (U.S.), Hybio Pharmaceutical Co., Ltd. (U.S.), and Senn Chemicals (Switzerland).

The driving factors of the peptide therapeutics contract API manufacturing market are the increasing focus on personalized medicine and targeted therapies is driving the demand for custom peptide synthesis and manufacturing services

North America region will lead the global peptide therapeutics contract API manufacturing market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client